Abbott Laboratories (ABT) Key Developments | Reuters.com
Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

38.53USD
29 Jun 2016
Change (% chg)

$0.97 (+2.58%)
Prev Close
$37.56
Open
$37.95
Day's High
$38.58
Day's Low
$37.95
Volume
4,778,325
Avg. Vol
9,196,173
52-wk High
$51.74
52-wk Low
$36.00

Latest Key Developments (Source: Significant Developments)

Mylan NV announces pricing of secondary public offering of portion of Abbott Laboratories' ordinary shares
Tuesday, 31 Mar 2015 07:47pm EDT 

Mylan NV:Says pricing of underwritten public offering of 35,000,000 ordinary shares held by certain subsidiaries of Abbott Laboratories, at $58.35 per share.Says that it has also granted underwriters an option to purchase additional 5,250,000 ordinary shares.Net proceeds from offering will be about $1.99 billion (or $2.29 billion if the option is exercised) after estimated underwriting discounts, commissions and offering expenses.Mylan will not sell any ordinary shares in offering and will not receive any of the proceeds from offering.5,000,000 ordinary shares being sold (or 40,250,000 ordinary shares if underwriters' option is exercised) represent 31.8 pct. or (36.6 pct. if the option is exercised) of the 110,000,000 ordinary shares currently owned by Abbott.Morgan Stanley & Co. LLC and Goldman, Sachs & Co. are acting as joint book-running managers for offering.  Full Article

Mylan completes acquisition of Abbott Laboratories's Non-U.S. developed markets specialty and branded generics business
Friday, 27 Feb 2015 12:30pm EST 

Mylan N.V. and Mylan Inc:Complete acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business.Under the previously announced terms of the transaction agreement, Abbott received 110 million shares of Mylan N.V., resulting in former Mylan Inc. shareholders now owning about 78pct of Mylan N.V. and Abbott now owning about 22pct of Mylan N.V. Mylan Inc.  Full Article

Abbott Laboratories declares quarterly dividend
Friday, 20 Feb 2015 10:36am EST 

Abbott Laboratories:Declares quarterly common dividend of 24 cents per share.Says cash dividend is payable May 15, to shareholders of record at the close of business on April 15.  Full Article

Abbott Laboratories gives FY, Q1 2015 EPS guidance in line with analysts' estimates
Thursday, 29 Jan 2015 07:45am EST 

Abbott Laboratories:Issues FY 2015 guidance for earnings-per-share (EPS) from continuing operations, excluding specified items, of $2.10 to $2.20.Including net specified items, projected earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) would be $1.33 to $1.43 for FY 2015.Issues Q1 2015 guidance for earnings-per-share guidance from continuing operations, excluding specified items, of $0.41 to $0.43.Including specified items, projected earnings-per-share from continuing operations under GAAP would be $0.18 to $0.20 for Q1 2015.FY 2015 EPS of $2.14 and Q1 2015 EPS of $0.41 - Thomson Reuters I/B/E/S.  Full Article

Abbott Laboratories completes acquisition of Topera, Inc.
Monday, 22 Dec 2014 04:30pm EST 

Abbott Laboratories:Completes its acquisition of Topera, Inc.Under the terms of the acquisition, Abbott acquired all outstanding equity of Topera for $250 mln upfront, plus potential future payments tied to performance milestones.  Full Article

Abbott Laboratories announces increase in quarterly dividend
Friday, 12 Dec 2014 11:18am EST 

Abbott Laboratories:Increases the company's quarterly common dividend to $0.24 per share from $0.22 per share.Payable Feb. 13, 2015, to shareholders of record on Jan. 15, 2015.  Full Article

Abbott Laboratories completes acquisition of Veropharm
Friday, 12 Dec 2014 12:03am EST 

Abbott Laboratories:Acquires control of Veropharm, a Russian pharmaceutical manufacturer.Through this acquisition, Abbott establishes a manufacturing footprint in Russia through Veropharm's production facilities, which include a new manufacturing facility currently under construction.Acquired control of Veropharm for 16.7 bln rubles (or about US$305 mln) through its purchase of Limited Liability Company Garden Hills, the holding company that currently owns about 98 pct of Veropharm.  Full Article

Abbott Laboratories to purchase Topera Inc
Wednesday, 29 Oct 2014 09:30am EDT 

Abbott Laboratories:Entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company focused on developing electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation.Completion of the Topera acquisition is subject to customary closing conditions, including antitrust clearance.Expected to close in the fourth quarter of this year.  Full Article

Abbott Laboratories narrows FY 2014 EPS outlook to a range above analysts' estimates; gives Q4 2014 EPS outlook in line with analysts' estimates
Wednesday, 22 Oct 2014 07:32am EDT 

Abbott Laboratories:Says it is raising the mid-point and narrowing its FY 2014 earnings-per-share guidance, excluding specified items, to $2.25 to $2.27 from $2.19 to $2.29, representing double-digit growth.Says including net specified items, projected earnings per share under GAAP would be $1.22 to $1.24 for FY 2014, including results from both continuing and discontinued operations.Expects Q4 2014 earnings-per-share guidance, excluding specified items, of $0.68 to $0.70, representing double-digit growth.Expects Q4 2014 including specified items, projected earnings-per-share under GAAP would be $0.32 to $0.34.FY 2014 EPS of $2.24 - Thomson Reuters I/B/E/S.Q4 2014 EPS of $0.70 - Thomson Reuters I/B/E/S.  Full Article

Abbott completes acquisition of CFR Pharmaceuticals
Friday, 26 Sep 2014 09:00am EDT 

Abbott Laboratories:Says has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding company's presence in fast-growing markets.Through purchase of controlling interest and tender offers described below, Abbott indirectly acquired more than 99 pct of CFR's ordinary shares for about $2.9 bln.  Full Article

BRIEF-Abbott announces results from study of Freestyle Libre system for type 1 diabetes

* Abbott announces positive results from groundbreaking study of Freestyle Libre system for people with type 1 diabetes